Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Capital Expenditures of $133000.0 for Q1 2026, up 209.3% year-over-year from $43000.0 in Q1 2025, and down 58.18% quarter-over-quarter from $318000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Capital Expenditures (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Capital Expenditures data on file, last reported at $133000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $133000.0, up 209.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $889000.0 (down 69.66% YoY), and the FY2025 annual result was $799000.0, down 74.02% from the prior year.
- Capital Expenditures slipped to $133000.0 in Q1 2026 per XENE's latest filing, from $318000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.2 million in Q1 2023 and troughed at $43000.0 in Q1 2025.
- A 5-year average of $736352.9 and a median of $386000.0 in 2022 frame the typical range for Capital Expenditures.
- On a YoY basis, Capital Expenditures climbed as much as 940.57% in 2023 and fell as far as 95.55% in 2023.
- A 5-year view of Capital Expenditures shows it stood at $1.8 million in 2022, then tumbled by 95.55% to $78000.0 in 2023, then jumped by 903.85% to $783000.0 in 2024, then tumbled by 59.39% to $318000.0 in 2025, then tumbled by 58.18% to $133000.0 in 2026.
- Business Quant data shows XENE's Capital Expenditures at $133000.0 in Q1 2026, $318000.0 in Q4 2025, and $281000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | 133,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 133,000.00 |
| Mar 31, 2026 | 133,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Dec 31, 2023 | 78,000.00 |